Official websites use. Share sensitive information only on official, secure websites. All authors have read and approved the final manuscript. This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. Diabetic nephropathy DN , affecting half of diabetic patients and contributing significantly to end-stage kidney disease, poses a substantial medical challenge requiring dialysis or transplantation.
The nuanced onset and clinical progression of kidney disease in diabetes involve consistent renal function decline and persistent albuminuria. To investigate Tiliroside's Til protective effect against diabetic nephropathy DN in rats under diabetic conditions. Biochemical markers, fasting blood glucose, food intake, kidney weight, antioxidant enzymes, inflammatory and fibrotic markers, and renal injury were monitored in different groups. Molecular docking analysis was performed to identify the interactions between Til and its targeted biomarkers.
Til significantly reduced biochemical markers, fasting blood glucose, food intake, and kidney weight and elevated antioxidant enzymes in diabetic rats. It also mitigated inflammatory and fibrotic markers, lessened renal injury, and displayed inhibitory potential against crucial markers associated with DN as demonstrated by molecular docking analysis. These findings suggest Til's potential as a therapeutic agent for DN treatment, highlighting its promise for future drug development.
Core Tip: Tiliroside Til demonstrates potent protective effects against diabetic nephropathy DN in rats, alongside glibenclamide. Through attenuating oxidative stress, inflammation, and fibrosis, Til treatment significantly improves renal function and reduces biochemical markers associated with DN.
Molecular docking analysis reveals its potential inhibition of key markers linked to the disease. These findings underscore Til's promising role as a therapeutic agent for DN, suggesting avenues for future drug development.
